Swiss artificial intelligence company Hilo (formerly Aktiia), specialized in the continuous monitoring and tracking of blood pressure, has closed a €37 million Series B funding round.
The round was co-led by Earlybird Health and Wellington Partners, and saw the entry of new investors, including Kfund and naturalX Health Ventures. Existing backers such as Redalpine, Khosla Ventures, Molten Ventures, Translink Capital, and Verve Ventures also participated.
Aktiia was founded in 2018 by Josep Solà, a Catalan entrepreneur based in Neuchâtel, and his co-founder Mattia Bertschi. The two spent 15 years at the prestigious Swiss research institute CSEM, where they focused on deciphering the language of the heart and deepening the scientific understanding of blood pressure. From that knowledge, they developed an innovative bracelet capable of measuring blood pressure continuously—up to 25 times a day—without the use of a cuff, supported by a mobile application.
As part of this funding milestone, the company has rebranded to Hilo and has now raised over $100 million in total funding. With the fresh capital, Hilo aims to accelerate its international expansion, with Spain among the new markets targeted. The Hilo Band is already available for purchase online at €230, and the company offers a €6 monthly subscription to unlock the full potential of the data collected through the mobile app linked to each device.
This investment comes at a time of strong momentum for the company, which recently achieved a major milestone with the CE marking of its smartphone camera-based blood pressure monitoring technology. The proceeds from this Series B will be used to continue product innovation, expand into new markets, and further develop its blood pressure intelligence platform for enterprise applications, according to El Economista.
The rebranding to Hilo reflects the company’s global ambition to make “clinically validated, cuffless blood pressure monitoring universally accessible and effortless,” company sources said in a statement.
“This funding round is a testament to the trust our investors place in Hilo’s groundbreaking technology and our mission to transform blood pressure management globally through more frequent, convenient, and accurate measurements. With billions affected by hypertension and only 20% of them achieving adequate control, the need for accessible and innovative solutions has never been greater.
Our transition to the name Hilo is more than a rebranding — it’s a commitment to delivering smarter tools that empower people everywhere to take charge of their health. We are deeply grateful to Aktiia’s early users for their support and to our new and returning investors for their continued confidence.”
Christoph Massner, Principal at Earlybird Health, who will join Hilo’s board of directors, added:
“Hilo sits at the intersection of medical-grade precision and consumer-centric accessibility. By combining a clinically validated medical device platform with an intuitive, user-friendly design, they bridge the gap between clinical reliability and everyday usability. It’s a rare combination that enables users to meaningfully take control of their health with minimal effort — a crucial advantage given the enormous unmet need, as uncontrolled hypertension remains one of the world’s leading causes of mortality.”
Johannes Fischer, Managing Partner at Wellington Partners, commented:
“We are delighted to co-lead this round and support Hilo’s groundbreaking technology, which represents a transformative step forward for the billions of people living with elevated blood pressure. We believe continuous, real-time access to blood pressure data will revolutionize how we approach the monitoring and treatment of one of the most prevalent health risks globally.”
Kfund’s participation in the round was made through its Leadwind fund, which is backed by Telefónica. Launched in 2022, this investment vehicle aims to attract both public and private capital to fund startups based in Southern Europe — with a priority on Spain — and Latin America, supporting companies with highly innovative and transformative technologies, known as deep tech scaleups. In addition to Telefónica as anchor investor, the fund includes prominent corporations such as BBVA and Catalana Occidente, among others.
cloud technology axon
The company generates annual revenues of approximately €90 million a...
